Paxlovid与COVID-19成人住院率降低相关——美国,2022年4月至9月
本研究利用美国大型电子健康记录数据集Cosmos,分析2022年4月至8月期间699,848名符合Paxlovid用药条件的≥18岁成人,评估开具Paxlovid处方与随后30天内COVID-19诊断住院之间的关联。结果显示,开具Paxlovid处方与总体研究人群住院率降低相关(aHR=0.49),在接种≥3剂mRNA COVID-19疫苗者(aHR=0.50)及各年龄组(18-49岁:aHR=0.59;50-64岁:aHR=0.40;≥65岁:aHR=0.53)中均观察到关联。作者建议应向符合条件的成人开具Paxlovid以降低COVID-19相关住院风险。
要点
- 在699,848名符合Paxlovid用药条件的成人中,28.4%在COVID-19诊断后5天内收到Paxlovid处方。
- 开具Paxlovid处方与总体研究人群住院率降低相关(aHR=0.49)。
- 接种≥3剂mRNA COVID-19疫苗者中aHR=0.50,18-49岁、50-64岁、≥65岁年龄组aHR分别为0.59、0.40、0.53。
核心结论
- 开具Paxlovid处方与总体研究人群住院率降低相关(aHR=0.49)。
- 作者建议应向符合条件的成人开具Paxlovid以降低COVID-19相关住院风险。
研究设计与样本
- 利用美国大型电子健康记录数据集Cosmos,分析2022年4月至8月期间699,848名≥18岁符合Paxlovid用药条件的成人。
- 采用Cox比例风险模型估计开具Paxlovid处方与随后30天内COVID-19诊断住院之间的关联,并校正人口学特征、地理位置、疫苗接种、既往感染和基础健康状况数量。
主要发现
- 在699,848名符合Paxlovid用药条件的成人中,28.4%在COVID-19诊断后5天内收到Paxlovid处方。
- 开具Paxlovid处方与总体研究人群住院率降低相关(aHR=0.49)。
- 在接种≥3剂mRNA COVID-19疫苗者中,开具Paxlovid处方与住院率降低相关(aHR=0.50)。
- 在各年龄组中,开具Paxlovid处方与住院率降低相关:18-49岁aHR=0.59;50-64岁aHR=0.40;≥65岁aHR=0.53。
关键数值与推荐
- Paxlovid为口服抗病毒药物,获授权用于有进展为重症风险的轻至中度COVID-19成人。
- 研究纳入标准为≥18岁且符合Paxlovid用药条件。
- 暴露定义为在COVID-19诊断后5天内收到Paxlovid处方。
- 结局定义为随后30天内因COVID-19诊断住院。
临床怎么用
- 作者建议应向符合条件的成人开具Paxlovid以降低COVID-19相关住院风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nirmatrelvir-ritonavir (Paxlovid), an oral antiviral treatment, is authorized for adults with mild-to-moderate COVID-19 who are at increased risk for progression to severe illness. However, real-world evidence on the benefit of Paxlovid, according to vaccination status, age group, and underlying health conditions, is limited. To examine the benefit of Paxlovid in adults aged ≥18 years in the United States, a large electronic health record (EHR) data set (Cosmos†) was analyzed to assess the association between receiving a prescription for Paxlovid and hospitalization with a COVID-19 diagnosis in the ensuing 30 days. A Cox proportional hazards model was used to estimate this association, adjusted for demographic characteristics, geographic location, vaccination, previous infection, and number of underlying health conditions. Among 699,848 adults aged ≥18 years eligible for Paxlovid during April-August 2022, 28.4% received a Paxlovid prescription within 5 days of COVID-19 diagnosis. Being prescribed Paxlovid was associated with a lower hospitalization rate among the overall study population (adjusted hazard ratio [aHR] = 0.49), among those who had received ≥3 mRNA COVID-19 vaccines (aHR = 0.50), and across age groups (18-49 years: aHR = 0.59; 50-64 years: aHR = 0.40; and ≥65 years: aHR = 0.53). Paxlovid should be prescribed to eligible adults to reduce the risk of COVID-19-associated hospitalization.
引用
- Shah MM, Joyce B, Plumb ID, et al. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36454693. doi:10.15585/mmwr.mm7148e2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。